

NeXT Liquid Biopsy™

It's time to think about more.

High-performance whole exome sequencing from plasma.

Highlights

- Comprehensively profile the tumor, exome-wide**
 Combined with ImmunID NeXT™, assess tumor heterogeneity, monitor response to therapy, and interrogate mechanisms of resistance
- Profile with ImmunID NeXT, Monitor with NeXT Liquid Biopsy**
 Leverage somatic variant results from the solid tumor, and monitor them for longitudinal analysis, while also detecting *de novo* mutations as they occur
- Discover more: Go beyond typical panel content**
 Exome-wide footprint ensures inclusion of important areas of tumor biology not typically covered in targeted panel approaches to fuel clinical and translational research
- Unprecedented performance at exome scale**
 Innovative library preparation, high depth of sequencing, and advanced error suppression techniques deliver results you can trust

Specifications

Workflow Step	Solution Attribute	Specification
Sample Preparation	Cancer Type & Stage	Late Stage (Stage IV) Solid Tumor Recommended
	Acceptable Sample Formats	Blood, Plasma, cfDNA
	Tube Types	Blood: Streck, EDTA Plasma: Standard Polypropylene
	cfDNA Required	50ng (Approx 20mL Blood; 8mL Plasma*)
Assay	Assay Size	34.8Mbp
	Assay Content	247 Boosted Cancer-Related Genes Whole Exome (~20,000 Genes)
	Sequencing Amount	≥250Gb/Sample
	Sequencing Coverage	Boosted Genes: ~5,000X (mean) Exome-Wide: ~2,000X (mean)
	Sequencing System	Illumina NovaSeq
	Sequencing Configuration	2 x 150 bp (Paired End)
Performance	Sensitivity – Boosted Genes (SNVs + Indels)	0.5%+ MAF: ≥95%
	Sensitivity – Exome-Wide (SNVs + Indels)	1%+ MAF: ≥85%
	Background Error Rate	≤0.6 False Positives Per Mbp
Deliverables	Reports	Standard ImmunID NeXT Deliverables Cell Free Data & QC Reports
General	Solid Tumor Required	Yes
	Matched Normal Required	Yes
	Analysis Modes	<i>De Novo</i> Variant Detection Variant Monitoring

*Volumes listed are general guidance, and vary dependent on cfDNA concentration in the sample.



Sales Contact

United States

info@personalis.com

Europe

europe@personalis.com

Other Countries

info@personalis.com

Personalis, Inc.

1330 O'Brien Drive, Menlo Park, CA 94025

+1 855-GENOME4 (436-6634) | +1 650-752-1300

www.personalis.com

@ 2020 Personalis, Inc. All rights reserved. Personalis®, ImmunogenomicsID™, NeoantigenID™, RepertoireID™, and NeXT Liquid Biopsy™, are trademarks of Personalis, Inc., ("Personalis") in the United States and/or other countries.

For Research Use Only. Not for use in diagnostic procedures.



Personalis®

102-347-B